- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02570373
A Study to Characterize the Elimination of Guselkumab Glycoform Variants in Healthy Participants
January 23, 2020 updated by: Janssen Research & Development, LLC
Phase 1, Open-label, Single-dose Study to Characterize the Elimination of Guselkumab Glycoform Variants in Healthy Subjects
The purpose of this study is to characterize the elimination of guselkumab glycoform variants following a single intravenous (IV) administration of guselkumab at a 10 milligram per kilogram (mg/kg) dose in healthy participants.
Study Overview
Detailed Description
This is an open-label single-dose study in healthy participants.
All participants will receive a single intravenous (IV) infusion of guselkumab at a dose of 10 milligram per kilogram (mg/kg) over 60 minutes on Day 1.
After the administration of study drug on Day 1, participants will stay in the clinical study unit until being discharged after the assessments on Day 2. Participants will be required to return to the study center for outpatient visits including safety assessments through Day 85 after study drug administration.
Participants' safety will be monitored throughout the study.
Study Type
Interventional
Enrollment (Actual)
8
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Arizona
-
Tempe, Arizona, United States
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 55 years (Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Participants must be a healthy man or woman with no clinically significant abnormalities on the basis of physical examination, medical history, vital signs, and 12-lead electrocardiogram (ECG) performed at Screening
- Participants must be otherwise healthy on the basis of clinical laboratory tests performed at Screening. If the results of the serum chemistry panel, hematology, or urinalysis are outside the normal reference ranges, the subject may be included only if the investigator judges the abnormalities or deviations from normal to be not clinically significant or to be appropriate and reasonable for the population under study. This determination must be recorded in the participant's source documents and initialed by the investigator
- Have a weight in the range of 60.0 kilogram (kg) to 100.0 kg, inclusive, if male; have a weight in the range of 50.0 kg to 90.0 kg, inclusive, if female. Have a body mass index of 18.5 kilogram per meter^2 (kg/m^2) to 30.0 kg/m^2, inclusive
- A woman must have a negative serum (beta human chorionic gonadotropin [beta hCG]) test at Screening and on Day -1
- Before drug administration, a woman must be either not of childbearing potential (Not of childbearing potential: Premenarchal; postmenopausal (greater than 45 years of age with amenorrhea for at least 12 months, or any age with amenorrhea for at least 6 months and a serum follicle stimulating hormone (FSH) level > 40 international Units/ Liter); permanently sterilized (eg, tubal occlusion, hysterectomy, bilateral salpingectomy); or otherwise be incapable of pregnancy) OR of childbearing potential and practicing a highly effective method of birth control consistent with local regulations regarding the use of birth control methods for subjects participating in clinical studies (established use of oral, injected or implanted hormonal methods of contraception; placement of an intrauterine device (IUD) or intrauterine system (IUS); barrier methods: condom with spermicidal foam/gel/film/cream/suppository or occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/suppository; male partner sterilization (the vasectomized partner should be the sole partner for that participant); true abstinence [when this is in line with the preferred and usual lifestyle of the participant])
Exclusion Criteria:
- Participant currently has or has a history of any clinically significant medical illness or medical disorders the investigator considers should exclude the subject, including (but not limited to), neuromuscular, hematological disease, immune deficiency state, respiratory disease, hepatic or gastrointestinal (GI) disease, neurological or psychiatric disease, ophthalmological disorders, neoplastic disease, renal or urinary tract diseases, or dermatological disease
- Participant is currently undergoing or has previously undergone allergy immunotherapy for a history of anaphylactic reactions
- Participant has had major surgery (eg, requiring general anesthesia) within 8 weeks before screening, or will not have fully recovered from surgery, or has surgery planned during the time the participant is expected to participate in the study (16 weeks)
- Participant has previously received guselkumab
- Participant has received an investigational drug (including investigational vaccines) or used an invasive investigational medical device within 3 months or 5 half-lives (whichever is longer) before the study drug administration
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Guselkumab
Participant will receive a single intravenous (IV) infusion of guselkumab at a dose of 10 milligram per kilogram (mg/kg) over 60 minutes on Day 1.
|
Participant will receive a single intravenous (IV) infusion of guselkumab at a dose of 10 milligram per kilogram (mg/kg) over 60 minutes on Day 1.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Rate of Elimination of Guselkumab Glycoform Variants Following a Single IV Administration of Guselkumab at a 10 mg/kg Dose in Healthy Participants
Time Frame: Up to 43 days
|
The composition of the glycoforms will be quantified and evaluated over time.
|
Up to 43 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants with Treatment Emergent Adverse Events (TEAEs) as a Measure of Safety and Tolerability of CNTO1959
Time Frame: up to 85 days
|
Participant incidence of treatment-emergent adverse events, vital signs, physical examinations, laboratory safety tests, and 12-lead electrocardiograms (ECG).
|
up to 85 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
September 25, 2015
Primary Completion (Actual)
January 12, 2016
Study Completion (Actual)
January 12, 2016
Study Registration Dates
First Submitted
September 16, 2015
First Submitted That Met QC Criteria
October 5, 2015
First Posted (Estimate)
October 7, 2015
Study Record Updates
Last Update Posted (Actual)
January 27, 2020
Last Update Submitted That Met QC Criteria
January 23, 2020
Last Verified
January 1, 2020
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- CR107879
- CNTO1959NAP1002 (Other Identifier: Janssen Research & Development, LLC)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
Clinical Trials on Guselkumab
-
Janssen Research & Development, LLCActive, not recruitingCrohn's DiseaseUnited States, Israel, Japan, Belgium, Lebanon, Taiwan, Netherlands, Russian Federation, Korea, Republic of, Jordan, France, Portugal, Turkey, Greece, Canada, Germany, Malaysia, Belarus, Latvia, Poland, Australia, Italy, Croatia, China, United Kingdom and more
-
University of California, San FranciscoJanssen Scientific Affairs, LLCRecruiting
-
University of California, San FranciscoJanssen Biotech, Inc.Recruiting
-
Janssen-Cilag Ltd.TerminatedPsoriasisItaly, Germany, Greece
-
Janssen Research & Development, LLCWithdrawn
-
Janssen Research & Development, LLCNo longer availableAdenomatous Polyposis Coli
-
University Medical Center GroningenJanssen-Cilag Ltd.CompletedHidradenitis SuppurativaNetherlands
-
Janssen-Cilag S.p.A.Completed
-
NYU Langone HealthJanssen Scientific Affairs, LLCRecruiting
-
Janssen Pharmaceutical K.K.Active, not recruiting